Experienced in Head and Neck Squamous Cell Carcinoma (HNSCC)

Dr. Mark B. Agulnik

Oncology
USC Care Medical Group Inc
1520 San Pablo St, 
Los Angeles, CA 
Offers Telehealth
Experienced in Head and Neck Squamous Cell Carcinoma (HNSCC)
USC Care Medical Group Inc
1520 San Pablo St, 
Los Angeles, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mark Agulnik is an Oncologist in Los Angeles, California. Dr. Agulnik is rated as an Experienced provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). His top areas of expertise are Adult Soft Tissue Sarcoma, Synovial Sarcoma, Angiosarcoma, Osteotomy, and Colonoscopy.

His clinical research consists of co-authoring 95 peer reviewed articles and participating in 27 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 8 articles and participated in 1 clinical trial in the study of Head and Neck Squamous Cell Carcinoma (HNSCC).

Specialties
Oncology
Licenses
Internal Medicine in IL
Hospital Affiliations
Keck Hospital Of USC
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

USC CARE MEDICAL GROUP INC
1520 San Pablo St, Los Angeles, CA 90033
Other Locations
USC CARE MEDICAL GROUP INC
1441 Eastlake Ave, Suite 2424, Los Angeles, CA 90089
USC CARE MEDICAL GROUP INC
125 W Hungtington Dr, Arcadia, CA 91007

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

27 Clinical Trials

A Phase 2 Study of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma
A Phase 2 Study of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma
Enrollment Status: Active_not_recruiting
Publish Date: December 05, 2025
Intervention Type: Procedure, Drug
Study Phase: Phase 2
Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)
Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)
Enrollment Status: Active_not_recruiting
Publish Date: December 01, 2025
Intervention Type: Drug, Radiation, Procedure
Study Drugs: Doxorubicin, Ifosfamide, Pazopanib
Study Phase: Phase 2/Phase 3
Phase 2 Study of Rogaratinib (BAY 1163877) in the Treatment of Patients With Sarcoma Harboring Alterations in Fibroblast Growth Factor Receptor (FGFR) 1-4 and SDH-Deficient Gastrointestinal Stromal Tumor (GIST)
Phase 2 Study of Rogaratinib (BAY 1163877) in the Treatment of Patients With Sarcoma Harboring Alterations in Fibroblast Growth Factor Receptor (FGFR) 1-4 and SDH-Deficient Gastrointestinal Stromal Tumor (GIST)
Enrollment Status: Active_not_recruiting
Publish Date: November 24, 2025
Intervention Type: Procedure, Drug
Study Drug: Rogaratinib
Study Phase: Phase 2
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naive, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects With Angiosarcoma
A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naive, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects With Angiosarcoma
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib-S-Malate, Nivolumab, Paclitaxel
Study Phase: Phase 2
Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, Alone or in Combination With Other Agents, in HLA-A2+ Participants With NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)
Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, Alone or in Combination With Other Agents, in HLA-A2+ Participants With NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)
Enrollment Status: Active_not_recruiting
Publish Date: July 16, 2025
Intervention Type: Drug
Study Drugs: Letetresgene Autoleucel, Fludarabine, Cyclophosphamide
Study Phase: Phase 2
A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
Enrollment Status: Completed
Publish Date: June 22, 2025
Intervention Type: Drug
Study Drug: Tazemetostat
Study Phase: Phase 2
A Phase II Study of Cabozantinib and Temozolomide in Patients With Unresectable or Metastatic Leiomyosarcoma and Other Soft Tissue Sarcomas
A Phase II Study of Cabozantinib and Temozolomide in Patients With Unresectable or Metastatic Leiomyosarcoma and Other Soft Tissue Sarcomas
Enrollment Status: Active_not_recruiting
Publish Date: May 13, 2025
Intervention Type: Other, Drug
Study Drugs: Cabozantinib, Temozolomide
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients With Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients With Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
Enrollment Status: Completed
Publish Date: January 31, 2025
Intervention Type: Drug
Study Drug: Nirogacestat Oral Tablet
Study Phase: Phase 3
A Phase II Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone in Patients With Previously Treated, Unresectable Myxoid Liposarcoma
A Phase II Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone in Patients With Previously Treated, Unresectable Myxoid Liposarcoma
Enrollment Status: Completed
Publish Date: January 27, 2025
Intervention Type: Drug
Study Drug: Efatutazone
Study Phase: Phase 2
A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR™ T Cells in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR™ T Cells in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Genetic
Study Phase: Phase 2
A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients With Unresectable or Metastatic Epithelioid Hemangioendothelioma
A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients With Unresectable or Metastatic Epithelioid Hemangioendothelioma
Enrollment Status: Completed
Publish Date: November 26, 2024
Intervention Type: Other, Drug
Study Drug: Trametinib
Study Phase: Phase 2
Phase I/Ib Study of Nivolumab and Veliparib in Patients With Advanced Solid Tumors and Lymphoma With and Without Alterations in Selected DNA Repair Genes
Phase I/Ib Study of Nivolumab and Veliparib in Patients With Advanced Solid Tumors and Lymphoma With and Without Alterations in Selected DNA Repair Genes
Enrollment Status: Completed
Publish Date: June 12, 2024
Intervention Type: Biological, Other, Drug
Study Drugs: Nivolumab, Veliparib
Study Phase: Phase 1
A Phase III Study of AL3818 (Anlotinib, Catequentinib) Hydrochloride Monotherapy in Subjects With Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma
A Phase III Study of AL3818 (Anlotinib, Catequentinib) Hydrochloride Monotherapy in Subjects With Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma
Enrollment Status: Active_not_recruiting
Publish Date: January 31, 2024
Intervention Type: Drug
Study Drugs: Anlotinib, Decarbazine
Study Phase: Phase 3
Phase II Study of Nivolumab and Ipilimumab for Treatment of Metastatic/Recurrent Adenoid Cystic Carcinoma of All Anatomic Sites of Origin and Non-adenoid Cystic Carcinoma Malignant Tumors of the Salivary Gland
Phase II Study of Nivolumab and Ipilimumab for Treatment of Metastatic/Recurrent Adenoid Cystic Carcinoma of All Anatomic Sites of Origin and Non-adenoid Cystic Carcinoma Malignant Tumors of the Salivary Gland
Enrollment Status: Active_not_recruiting
Publish Date: January 18, 2024
Intervention Type: Biological, Other
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes
SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes
Enrollment Status: Completed
Publish Date: November 07, 2023
Intervention Type: Drug
Study Drug: Regorafenib
Study Phase: Phase 2
ROMAN: Reduction in Oral Mucositis With Avasopasem Manganese (GC4419) - Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer
ROMAN: Reduction in Oral Mucositis With Avasopasem Manganese (GC4419) - Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer
Enrollment Status: Completed
Publish Date: October 24, 2023
Intervention Type: Drug
Study Drug: GC4419
Study Phase: Phase 3
Carboplatin-Paclitaxel Induction Chemotherapy and ABT-888 (Veliparib) - a Phase 1/Randomized Phase 2 Study in Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck
Carboplatin-Paclitaxel Induction Chemotherapy and ABT-888 (Veliparib) - a Phase 1/Randomized Phase 2 Study in Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck
Enrollment Status: Completed
Publish Date: June 07, 2023
Intervention Type: Other, Drug, Radiation
Study Drugs: Carboplatin, Cisplatin, 5-Fluorouracil, Hydroxyurea, Paclitaxel, Veliparib
Study Phase: Phase 1/Phase 2
A Phase I/II Open-Label Trial of CPI-613® (Devimistat) Plus Hydroxychloroquine to Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue
A Phase I/II Open-Label Trial of CPI-613® (Devimistat) Plus Hydroxychloroquine to Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue
Enrollment Status: Completed
Publish Date: May 24, 2023
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
Enrollment Status: Completed
Publish Date: January 23, 2023
Intervention Type: Drug
Study Drug: Selinexor
Study Phase: Phase 2/Phase 3
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
Enrollment Status: Completed
Publish Date: October 06, 2022
Intervention Type: Drug
Study Drugs: Avapritinib, Regorafenib
Study Phase: Phase 3
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) VS. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) VS. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Enrollment Status: Terminated
Publish Date: August 23, 2022
Intervention Type: Drug
Study Drugs: Pazopanib, Pazopanib Hydrochloride, Sapanisertib
Study Phase: Phase 1/Phase 2
Phase II Study Evaluating the Role of Pazopanib in Angiosarcoma
Phase II Study Evaluating the Role of Pazopanib in Angiosarcoma
Enrollment Status: Completed
Publish Date: August 19, 2022
Intervention Type: Procedure, Other, Radiation, Drug
Study Drugs: Pazopanib, F-18 Fludeoxyglucose
Study Phase: Phase 2
A Phase II Study of Pazopanib With Oral Topotecan in Patients With Metastatic and Non-resectable Soft Tissue and Bone Sarcomas
A Phase II Study of Pazopanib With Oral Topotecan in Patients With Metastatic and Non-resectable Soft Tissue and Bone Sarcomas
Enrollment Status: Completed
Publish Date: June 07, 2022
Intervention Type: Drug, Other
Study Drugs: Pazopanib Hydrochloride, Topotecan Hydrochloride
Study Phase: Phase 2
Multicenter, Open-Label Phase II Study of Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma
Multicenter, Open-Label Phase II Study of Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma
Enrollment Status: Completed
Publish Date: April 25, 2022
Intervention Type: Drug
Study Drug: Regorafenib
Study Phase: Phase 2
A Phase II Study of Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy
A Phase II Study of Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy
Enrollment Status: Completed
Publish Date: August 05, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Phase II Window of Opportunity Trial of Ipilimumab and Nivolumab in Metastatic Recurrent HER2- Inflammatory Breast Cancer (IBC) The Win Trial
A Phase II Window of Opportunity Trial of Ipilimumab and Nivolumab in Metastatic Recurrent HER2- Inflammatory Breast Cancer (IBC) The Win Trial
Enrollment Status: Terminated
Publish Date: July 16, 2020
Intervention Type: Biological, Other
Study Phase: Phase 2
View 26 Less Clinical Trials

95 Total Publications

Chondrosarcoma: Clinical Behavior, Molecular Mechanisms, and Emerging Therapeutic Strategies.
Chondrosarcoma: Clinical Behavior, Molecular Mechanisms, and Emerging Therapeutic Strategies.
Journal: Critical reviews in oncology/hematology
Published: July 01, 2025
Similar Doctors
Distinguished in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. Victoria M. Villaflor
Oncology | Hematology
Distinguished in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. Victoria M. Villaflor
Oncology | Hematology

Uc Regents

101 The City Dr S, 
Orange, CA 
 (26.1 miles away)
714-456-7004
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Victoria Villaflor is an Oncologist and a Hematologist in Orange, California. Dr. Villaflor is rated as a Distinguished provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). Her top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Salivary Gland Tumors, Gastrostomy, and Tissue Biopsy.

Advanced in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. Deborah Wong
Hematology | Oncology
Advanced in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. Deborah Wong
Hematology | Oncology

The Regents Of The University Of California

200 Medical Plz, 
Los Angeles, CA 
 (13.9 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Deborah Wong is a Hematologist and an Oncologist in Los Angeles, California. Dr. Wong is rated as a Distinguished provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). Her top areas of expertise are Lung Cancer, Inflammatory Breast Cancer, Nasopharyngeal Carcinoma, and Oral Squamous Cell Carcinoma.

Advanced in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. Alain C. Mita
Oncology | Hematology
Advanced in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. Alain C. Mita
Oncology | Hematology

Hoag Clinic

1 Hoag Dr, Suite 107, 
Newport Beach, CA 
 (34.1 miles away)
949-764-5347
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Alain Mita is an Oncologist and a Hematologist in Newport Beach, California. Dr. Mita is rated as an Advanced provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). His top areas of expertise are Lung Cancer, Small Cell Lung Cancer (SCLC), Polymorphous Low Grade Adenocarcinoma, and Non-Small Cell Lung Cancer (NSCLC).

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Agulnik's expertise for a condition
ConditionClose
View All 8 Elite Conditions
View All 17 Distinguished Conditions
View All 73 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile